{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T22:48:54Z","timestamp":1789858134491,"version":"4.0.1"},"reference-count":45,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2018,11,9]],"date-time":"2018-11-09T00:00:00Z","timestamp":1541721600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0204573","type":"journal-article","created":{"date-parts":[[2018,11,9]],"date-time":"2018-11-09T18:58:32Z","timestamp":1541789912000},"page":"e0204573","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Surveillance of adverse drug events associated with etanercept prescribed for juvenile idiopathic arthritis in a single center up to 9-years: A retrospective observational study"],"prefix":"10.1371","volume":"13","author":[{"given":"Jeong Yun","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jee Eun","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Hyun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon Sook","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Woo","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7831-7740","authenticated-orcid":true,"given":"Soo An","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2018,11,9]]},"reference":[{"issue":"9783","key":"ref1","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1016\/S0140-6736(11)60244-4","article-title":"Juvenile idiopathic arthritis","volume":"377","author":"B Prakken","year":"2011","journal-title":"Lancet"},{"issue":"7","key":"ref2","first-page":"1377","article-title":"Epidemiology of juvenile idiopathic arthritis in Alsace, France","volume":"33","author":"S Danner","year":"2006","journal-title":"The Journal of rheumatology"},{"issue":"1\u20132","key":"ref3","first-page":"72","article-title":"Update on treatment of arthritis in children: new treatments, new goals","volume":"64","author":"DJ Lovell","year":"2006","journal-title":"Bulletin of the NYU hospital for joint diseases"},{"issue":"9","key":"ref4","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1002\/art.10444","article-title":"Long-term outcome in patients with juvenile idiopathic arthritis","volume":"46","author":"K Minden","year":"2002","journal-title":"Arthritis and rheumatism"},{"issue":"10","key":"ref5","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/nm939","article-title":"Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases","volume":"9","author":"M Feldmann","year":"2003","journal-title":"Nature medicine"},{"issue":"3","key":"ref6","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2165\/00148581-200406030-00001","article-title":"Biologic agents for the treatment of juvenile rheumatoid arthritis: current status","volume":"6","author":"R Carrasco","year":"2004","journal-title":"Paediatric drugs"},{"issue":"10","key":"ref7","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1002\/acr.22087","article-title":"2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications","volume":"65","author":"S Ringold","year":"2013","journal-title":"Arthritis care & research"},{"issue":"6","key":"ref8","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.semarthrit.2012.10.006","article-title":"The use of biologic response modifiers in polyarticular-course juvenile idiopathic arthritis: a systematic review","volume":"42","author":"WJ Ungar","year":"2013","journal-title":"Seminars in arthritis and rheumatism"},{"issue":"2","key":"ref9","first-page":"252","article-title":"Safety of anti-TNFalpha therapy in children with juvenile idiopathic arthritis","volume":"22","author":"L Dekker","year":"2004","journal-title":"Clinical and experimental rheumatology"},{"issue":"4","key":"ref10","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1002\/art.34348","article-title":"Rates of malignancy associated with juvenile idiopathic arthritis and its treatment","volume":"64","author":"T Beukelman","year":"2012","journal-title":"Arthritis and rheumatism"},{"issue":"8","key":"ref11","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1002\/art.34458","article-title":"Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment","volume":"64","author":"T Beukelman","year":"2012","journal-title":"Arthritis and rheumatism"},{"issue":"11","key":"ref12","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJM200003163421103","article-title":"Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group","volume":"342","author":"DJ Lovell","year":"2000","journal-title":"The New England journal of medicine"},{"issue":"6","key":"ref13","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1002\/art.21885","article-title":"Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis","volume":"54","author":"DJ Lovell","year":"2006","journal-title":"Arthritis and rheumatism"},{"issue":"5","key":"ref14","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/art.23427","article-title":"Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis","volume":"58","author":"DJ Lovell","year":"2008","journal-title":"Arthritis and rheumatism"},{"issue":"5","key":"ref15","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1136\/ard.2007.087411","article-title":"Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register","volume":"68","author":"FH Prince","year":"2009","journal-title":"Annals of the rheumatic diseases"},{"issue":"5","key":"ref16","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1136\/annrheumdis-2011-201060","article-title":"Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC Register","volume":"72","author":"MH Otten","year":"2013","journal-title":"Annals of the rheumatic diseases"},{"issue":"12","key":"ref17","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1136\/ard.2003.014886","article-title":"The German etanercept registry for treatment of juvenile idiopathic arthritis","volume":"63","author":"G Horneff","year":"2004","journal-title":"Annals of the rheumatic diseases"},{"key":"ref18","unstructured":"Association WM. Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.wma.net\/en\/30publications\/10policies\/b3\/index.html\" xlink:type=\"simple\">http:\/\/www.wma.net\/en\/30publications\/10policies\/b3\/index.html<\/ext-link>. Accessed July 30, 2015."},{"key":"ref19","first-page":"1","volume":"498","year":"1972"},{"key":"ref20","unstructured":"Organization WH. WHO-UMC causality assessment. 2012. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.who-umc.org\/DynPage.aspx?id=98029&quicksearchquery=umc+category\" xlink:type=\"simple\">http:\/\/www.who-umc.org\/DynPage.aspx?id=98029&amp;quicksearchquery=umc+category<\/ext-link> Accessed June 30, 2016."},{"issue":"9237","key":"ref21","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","article-title":"Adverse drug reactions: definitions, diagnosis, and management","volume":"356","author":"IR Edwards","year":"2000","journal-title":"Lancet"},{"issue":"9","key":"ref22","first-page":"2229","article-title":"Preventability and severity assessment in reporting adverse drug reactions","volume":"49","author":"SC Hartwig","year":"1992","journal-title":"American journal of hospital pharmacy"},{"issue":"7","key":"ref23","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1136\/annrheumdis-2013-204641","article-title":"Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register","volume":"74","author":"MH Otten","year":"2015","journal-title":"Annals of the rheumatic diseases"},{"issue":"8","key":"ref24","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1136\/ard.2007.069484","article-title":"Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients","volume":"67","author":"V Gerloni","year":"2008","journal-title":"Annals of the rheumatic diseases"},{"issue":"11","key":"ref25","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1517\/14712598.2013.840580","article-title":"Etanercept (Enbrel) in the treatment of juvenile idiopathic arthritis","volume":"13","author":"RA Berard","year":"2013","journal-title":"Expert opinion on biological therapy"},{"issue":"7","key":"ref26","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1517\/14740338.2015.1042453","article-title":"Safety of biologic therapies for the treatment of juvenile idiopathic arthritis","volume":"14","author":"G. Horneff","year":"2015","journal-title":"Expert opinion on drug safety"},{"issue":"6","key":"ref27","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1136\/annrheumdis-2012-203046","article-title":"Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study","volume":"73","author":"G Horneff","year":"2014","journal-title":"Annals of the rheumatic diseases"},{"issue":"6","key":"ref28","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1002\/art.34343","article-title":"Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis","volume":"64","author":"CA Wallace","year":"2012","journal-title":"Arthritis and rheumatism"},{"key":"ref29","unstructured":"Organization WH. Global tuberculosis report 2015. Available from: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.who.int\/tb\/publications\/global_report\/en\/\" xlink:type=\"simple\">http:\/\/www.who.int\/tb\/publications\/global_report\/en\/<\/ext-link> Accessed on July 31, 2017 [cited 2017 on July 31]."},{"issue":"1","key":"ref30","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/art.10710","article-title":"Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis\u2014Interim results from an ongoing multicenter, open-label, extended-treatment trial","volume":"48","author":"DJ Lovell","year":"2003","journal-title":"Arthritis and rheumatism"},{"issue":"2","key":"ref31","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2147\/tcrm.2007.3.2.245","article-title":"The safety of etanercept for the treatment of plaque psoriasis","volume":"3","author":"KA Papp","year":"2007","journal-title":"Therapeutics and clinical risk management"},{"issue":"6","key":"ref32","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1517\/14740338.2012.727796","article-title":"Etanercept-induced injection site reactions: potential pathomechanisms and clinical assessment","volume":"11","author":"A Batycka-Baran","year":"2012","journal-title":"Expert opinion on drug safety"},{"issue":"7","key":"ref33","first-page":"893","article-title":"Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor alpha receptor: Fc fusion protein","volume":"137","author":"R Zeltser","year":"2001","journal-title":"Archives of dermatology"},{"key":"ref34","unstructured":"etanercept) E. Instructions for Use. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/pi.amgen.com\/~\/media\/amgen\/repositorysites\/pi-amgen-com\/enbrel\/enbrel_pi.pdf\" xlink:type=\"simple\">https:\/\/pi.amgen.com\/~\/media\/amgen\/repositorysites\/pi-amgen-com\/enbrel\/enbrel_pi.pdf<\/ext-link> Accessed June 6, 2018."},{"issue":"4","key":"ref35","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1136\/ard.2007.087593","article-title":"Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry","volume":"68","author":"G Horneff","year":"2009","journal-title":"Annals of the rheumatic diseases"},{"issue":"2","key":"ref36","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/art.22381","article-title":"Prevalence, risk factors, and outcome of uveitis in juvenile idiopathic arthritis: a long-term followup study","volume":"56","author":"RK Saurenmann","year":"2007","journal-title":"Arthritis and rheumatism"},{"issue":"1","key":"ref37","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1546-0096-11-45","article-title":"Profiling risk factors for chronic uveitis in juvenile idiopathic arthritis: a new model for EHR-based research","volume":"11","author":"TS Cole","year":"2013","journal-title":"Pediatric rheumatology online journal"},{"issue":"11","key":"ref38","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1002\/acr.22613","article-title":"Uveitis Events During Adalimumab, Etanercept, and Methotrexate Therapy in Juvenile Idiopathic Arthritis: Data From the Biologics in Pediatric Rheumatology Registry","volume":"67","author":"I Foeldvari","year":"2015","journal-title":"Arthritis care & research"},{"issue":"5","key":"ref39","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1177\/112067210701700509","article-title":"Methotrexate for uveitis associated with juvenile idiopathic arthritis: value and requirement for additional anti-inflammatory medication","volume":"17","author":"A Heiligenhaus","year":"2007","journal-title":"European journal of ophthalmology"},{"issue":"2","key":"ref40","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ajo.2010.08.021","article-title":"Relapse rate of uveitis post-methotrexate treatment in juvenile idiopathic arthritis","volume":"151","author":"V Kalinina Ayuso","year":"2011","journal-title":"American journal of ophthalmology"},{"issue":"6","key":"ref41","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1002\/art.22709","article-title":"Epidemiology of juvenile idiopathic arthritis in a multiethnic cohort: ethnicity as a risk factor","volume":"56","author":"RK Saurenmann","year":"2007","journal-title":"Arthritis and rheumatism"},{"issue":"7","key":"ref42","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s10067-013-2232-4","article-title":"Clinical analysis in 202 children with juvenile idiopathic arthritis","volume":"32","author":"H Huang","year":"2013","journal-title":"Clinical rheumatology"},{"issue":"5","key":"ref43","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1080\/03009740801998762","article-title":"Prevalence and patterns of anti-nuclear antibodies in Korean children with juvenile idiopathic arthritis according to ILAR criteria","volume":"37","author":"JI Shin","year":"2008","journal-title":"Scandinavian journal of rheumatology"},{"issue":"5","key":"ref44","doi-asserted-by":"crossref","first-page":"720","DOI":"10.3109\/s10165-011-0578-5","article-title":"Safety and efficacy of long-term etanercept in the treatment of methotrexate-refractory polyarticular-course juvenile idiopathic arthritis in Japan","volume":"22","author":"M Mori","year":"2012","journal-title":"Modern rheumatology \/ the Japan Rheumatism Association"},{"issue":"9","key":"ref45","first-page":"1974","article-title":"Comparison of pharmacy-based concurrent surveillance and medical record retrospective reporting of adverse drug reactions","volume":"48","author":"GT Schumock","year":"1991","journal-title":"American journal of hospital pharmacy"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0204573","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T06:54:14Z","timestamp":1720767254000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0204573"}},"subtitle":[],"editor":[{"given":"Andrea","family":"Martinuzzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,11,9]]},"references-count":45,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2018,11,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0204573","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,9]]}}}